Verastem (NasdaqCM:VSTM) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsClara Dong - VP of Equity Research in BiotechnologyDan Calkins - CFODan Paterson - President and CEOJulissa Viana - VP of Corporate Communications, Investor Relations, and Patient AdvocacyMatthew Venezia - Biotechnology Equity Research AssociateMichael Kauffman - President of DevelopmentMike Crowther - Chief Commercial OfficerYuan Zhi - Managing DirectorConference Call ParticipantsEric Schmidt - Biotechnology Analy ...

BillionToOne (NasdaqGS:BLLN) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsBrandon Couillard - Managing DirectorCasey Woodring - VP of Equity ResearchDan Arias - Managing DirectorDavid Deichler - Head of Investor RelationsDavid Westenberg - Managing Director of Equity ResearchOzan Atay - Co-founder and CEORoss Taylor - CFOConference Call ParticipantsAndrew Brackmann - Equity Research AnalystMark Massaro - Managing Director and Senior Equity Research AnalystSubbu Nambi - Managing Direc ...

OmniAb (NasdaqGM:OABI) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsJoseph Pantginis - Managing DirectorKurt Gustafson - EVP and CFOMatthew Foehr - President and CEOStephen D. Willey - Managing DirectorConference Call ParticipantsJacqueline Kisa - Biotechnology Specialist and AnalystMatthew Hewitt - Senior Research AnalystMichael G. King, Jr. - Managing Director and Senior Biotechnology AnalystPuneet Souda - Senior Research AnalystNone - AnalystOperatorGood afternoon, welcome to Omni ...

American Eagle Outfitters (NYSE:AEO) Q4 2026 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsCorey Tarlowe - Senior Vice President of Equity ResearchDana Telsey - CEO and Chief Research OfficerJanet Kloppenburg - PresidentJay Sole - Managing DirectorJennifer Foyle - President and Executive DirectorJudy Meehan - Head of Investor Relations and Corporate CommunicationsMarni Shapiro - Managing PartnerMike Matthias - CFOPaul Lejuez - Managing DirectorNone - Company RepresentativeConference Call Part ...

Niagen Bioscience (NasdaqCM:CDXC) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsAndrew Shao - SVP of Global Regulatory and Scientific AffairsJeffrey Cohen - Managing Director of Equity ResearchKendall Knysch - Senior Director of Publicity and Public RelationsOzan Pamir - CFORam Selvaraju - Managing Director of Equity ResearchRob Fried - CEOSusan Anderson - Managing DirectorConference Call ParticipantsSean McGowan - Managing Director and Senior Research AnalystOperatorLadies and gentle ...

Pulmonx (NasdaqGS:LUNG) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsAnnie Tripodo - Equity Research AssociateDerrick Sung - COO and CFOGlen French - President and CEOLaine Morgan - Head of Investor RelationsSimran Kaur - Equity Research AssociateConference Call ParticipantsJason Bednar - Managing Director and Senior Research AnalystJon Young - Director and Equity Research AnalystNelson Cox - Equity Research AnalystOperatorThank you for standing by. Welcome to the Pulmonx Q4 2025 ear ...

American Eagle Outfitters (NYSE:AEO) Q4 2026 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsCorey Tarlowe - Senior Vice President of Equity ResearchDana Telsey - CEO and Chief Research OfficerJanet Kloppenburg - PresidentJay Sole - Managing DirectorJennifer Foyle - President and Executive DirectorJudy Meehan - Head of Investor Relations and Corporate CommunicationsMarni Shapiro - Managing PartnerMike Matthias - CFOPaul Lejuez - Managing DirectorNone - Company RepresentativeConference Call Part ...

Grocery Outlet (NasdaqGS:GO) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsChris Miller - CFOEdward Kelly - Managing Director of Equity ResearchIan Ferry - VP of Strategic Finance and Investor RelationsJason Potter - President and CEOJoe Feldman - Senior Managing Director and Assistant Director of ResearchJohn Heinbockel - Managing DirectorKylie Cohu - VP of Consumer Equity ResearchOliver Chen - Managing Director and Retail, Luxury, and New Platforms Sector HeadConference Call Partici ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [24] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [28] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [26] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [30] Business Line Data and Key Metrics Changes - The company had 107 partners running 407 active programs by year-end 2025, reflecting growth in both partner count and program activity [4][7] - There were 84 program additions in 2025, significantly higher than previous years, with a net increase of 44 programs during the year [9] - Over 98% of active programs have contracted future economics to the company, with total contracted milestone payments exceeding $3 billion [10] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [8] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's partner relationships [8] Company Strategy and Development Direction - The company introduced OmniUltra, a transgenic chicken platform for ultra-long CDRH3s, which is expected to drive growth and attract new partners [5][20] - The xPloration platform, launched in mid-2025, is positioned for significant growth and aims to enhance partner engagement through high-throughput screening capabilities [6][22] - The company is focused on transitioning revenue from milestone-driven to more royalty-driven streams, with an average royalty rate of 3.4% across its portfolio [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong partner engagement and the potential for multiple new clinical program entries in 2026 [19][55] - The company anticipates achieving cash flow positivity as it continues to control operating costs while expanding its partner and program portfolio [32] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments, with expectations to end 2026 with a cash balance of $30 million to $35 million [30] - The company implemented workforce reductions of 22 employees in 2025, contributing to lower operating expenses [29] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [34][36] Question: Revenue expectations from xPloration - Management indicated that xPloration is expected to contribute significantly to revenue in 2026, with strong interest from high-tier partners [38][40] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [43][47] Question: Deployment of xPloration systems - Two xPloration instruments were deployed by the end of 2025, with expectations for growth in 2026 [52] Question: Initial response to OmniUltra - The launch of OmniUltra has been well-received, with strong engagement from partners and an increase in partner programs [62][64] Question: Milestones for OmniUltra in 2026 - The focus for 2026 will be on adding partners and programs leveraging OmniUltra technology [74] Question: Royalty structures for active programs - The majority of active programs have flat royalties, with some having tiered structures [78][81]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [6][24] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million [7][26] - The company ended the year with $64.8 million in cash and no debt, reinforcing financial stability [30] Business Line Data and Key Metrics Changes - Revenue from Tru Niagen grew by 21% to $27.5 million, primarily driven by e-commerce sales of $20.2 million, which increased by 17% [26][28] - Niagen ingredient revenue was $5.6 million, up 5% year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [27] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [27] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home injection kits through a telehealth platform [10] - The market for NAD products is growing, with increased competition, particularly from NMN products [8][11] Company Strategy and Development Direction - The company aims to build on its strong foundation in NAD science, focusing on expanding its product offerings and market presence [8][10] - Plans include launching Niagen Plus branded at-home injection kits and expanding into the beauty cosmetics market [10][11] - The company is pursuing litigation against the FDA regarding NMN products, believing it has a strong case [11][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong performance in 2026 despite challenges from increased competition [8] - The company anticipates 10%-15% growth in net sales for 2026, with a slight improvement in gross margin [32][33] - Management emphasized the importance of scientific integrity and continued investment in R&D to support innovation [29] Other Important Information - The company divested its ChromaDex Reference Standards business to streamline operations and focus on core activities [13][32] - A recent patent was secured for NR and derivatives in intravenous and injectable formulations, indicating potential growth opportunities [10] Q&A Session Summary Question: Discussion on injections and SKUs - The company plans to initially offer one SKU for injections, targeting the biohacker community and expanding to other audiences later [40] Question: Guidance for the year - Management indicated that guidance is conservative, reflecting a cautious approach to revenue projections [43] Question: Growth drivers for the year - Growth is expected from existing products, new distribution channels, and increased awareness of Niagen and Tru Niagen [50] Question: Legal proceedings against the FDA - Management believes the lawsuit will not significantly impact costs and expects a summary judgment [62] Question: Share repurchase strategy - The company plans to utilize its $10 million buyback program more actively in the future [65]